INTS vs NBIX
Intensity Therapeutics, Inc. Common stock (INTS) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
INTS does not have a complete income-statement cache yet.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
INTS currently screens at market cap $7.7M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the INTS and NBIX stock pages for the full models.
Not investment advice.